You are here: Industry Insights > inhibitor

News List

Dipeptidyl Peptidase-4 Inhibitors May Up Pancreatic Disease Risk drugs
August 29, 2019
Use of dipeptidyl peptidase-4 inhibitors (DPP-4i) is associated with increased risks for pancreatitis and pancreatic cancer in patients with newly diagnosed type 2 diabetes...
SGLT-2 Inhibitor Use Not Linked to Increased Risk for UTI Events drugs
July 31, 2019
Initiation of therapy with sodium-glucose cotransporter-2 (SGLT-2) inhibitors for type 2 diabetes mellitus is not associated with an increased risk for...
Periop Diabetic Ketoacidosis Seen in Patients on SGLT2 Inhibitors drugs
July 25, 2019
Sodium-glucose cotransporter-2 inhibitor (SGLT2i)-associated diabetic ketoacidosis (DKA) may occur after surgery even in patients...
AUM Biosciences to develop Inflection’s cancer therapy pharmaceutical-technology
July 19, 2019
Biotechnology firm AUM Biosciences has entered a global licence agreement for Inflection Biosciences’ series of PIM/PI3K/mTOR inhibitor molecules.
Syndax Announces FDA Clearance of IND Application for Targeted Menin Inhibitor americanpharmaceuticalreview
July 11, 2019
Syndax Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to begin a Phase 1/2 trial for SNDX-5613, a targeted Menin inhibitor, in patients with relapsed/refractory (R
Excess Cause-Specific Mortality Tied to Chronic Proton Pump Inhibitor Use drugs
June 03, 2019
Excess Cause-Specific Mortality Tied to Chronic Proton Pump Inhibitor Use.
First PI3K inhibitor for breast cancer approved by FDA europeanpharmaceuticalreview
May 30, 2019
The US Food and Drug Administration (FDA) has approved Piqray (alpelisib) tablets to treat patients with breast cancer.
IL-18 inhibitor drug holds great potential for inflammatory diseases europeanpharmaceuticalreview
April 26, 2019
An international team of researchers has identified the key role that IL-18 protein plays in Still’s disease, making it a prime candidate for IL-18 inhibitor drug that is proving promising in current trials.
AACR: Bayer posts early clinical data on follow-up to Loxo's Vitrakvi fiercebiotech
April 03, 2019
Bayer has shared preliminary clinical data on the second TRK inhibitor it licensed from Loxo Oncology.
CStone received IND approval in China for HDAC6 inhibitor CS3003 en-cphi.cn
March 13, 2019
Cstone announced that the National Medical Products Administration (NMPA) recently approved company's histone deacetylase 6 (HDAC6) selective inhibitor CS3003 for Phase I clinical trial in China.